AZA Combined with R-GemOx for Elderly DLBCL Patients

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Jan 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment approach for elderly patients with diffuse large B-cell lymphoma (DLBCL), which is a type of blood cancer. The trial will study the safety and effectiveness of combining two treatments: AZA (azacytidine) and R-GemOx (a mix of rituximab, gemcitabine, and oxaliplatin). This study is specifically for patients aged 60 and older who have been diagnosed with DLBCL and have not received any previous chemotherapy or radiation for their condition.

To be eligible for this trial, participants must understand the study and willingly agree to take part by signing a consent form. They need to have at least one measurable tumor that can be evaluated according to specific guidelines. This trial is not yet recruiting participants, but once it starts, those who join can expect to receive the new treatment and be monitored closely for its effects. It's important to note that certain patients, such as those with other types of lymphoma or specific health issues, may not be able to participate.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • 1. Subjects fully understand and voluntarily participate in this study and sign informed consent.
• • 2. Aged ≥60 years, both male and female.
• • 3. Pathologically confirmed DLBCL
• • 4. There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.
• • 5. No previous chemotherapy or radiotherapy for DLBCL has been received.
• • 6. Expected survival ≥3 months.
• Key Exclusion Criteria:
• • 1. DLBCL combined with other types of lymphoma. Transformed DLBCL.
• • 2. DLBCL with central nervous system invasion.
• • 3. The patients have contraindications to any drug in the combined treatment.
• • 4. Patients with the infection of human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome.
• • 5. Mentally ill persons or persons unable to obtain informed consent.
• • 6. The investigators think that the patient is not suitable for the study.